SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 174.80+2.9%Dec 19 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (1047)6/15/1999 3:30:00 AM
From: Walkingshadow  Read Replies (1) of 1686
 
Harold--

Thanks for the post--good work!

One question I have regards Adentri. CHF is an area where there are many current drugs already out, and many more in various pipelines. How do you think Adentri might fare against these drugs, and why? While you may talk about the size of the potential market, this does not seem as relevant as asking: What might be the ability of Adentri to grab market share and command sales, and how long might this last? (to answer this last question, you would have to compare Adentri's advantages/disadvantages to those of CHF drugs in other pipelines).

Any thoughts on these questions?

Thanks,

Walkingshadow
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News